{"nctId":"NCT01753557","briefTitle":"Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C","startDateStruct":{"date":"2012-12"},"conditions":["Chronic Hepatitis C (CHC)"],"count":54,"armGroups":[{"label":"Treatment-Naive","type":"EXPERIMENTAL","interventionNames":["Drug: MP-424","Drug: RBV","Drug: PEG-IFN alfa-2a"]},{"label":"Treatment-Relapsed","type":"EXPERIMENTAL","interventionNames":["Drug: MP-424","Drug: RBV","Drug: PEG-IFN alfa-2a"]}],"interventions":[{"name":"MP-424","otherNames":[]},{"name":"RBV","otherNames":[]},{"name":"PEG-IFN alfa-2a","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Genotype 1 CHC\n* treatment-naïve or relapsers (patient who relapsed after previous treatment)\n* Able and willing to follow contraception requirements\n\nExclusion Criteria:\n\n* Cirrhosis of the liver or hepatic failure\n* Hepatitis B surface antigen-positive or HIV (Human Immunodeficiency Virus) antibodies-positive\n* History of, or concurrent hepatocellular carcinoma\n* History of, or concurrent depression, schizophrenia, or suicide attempt in the past\n* Pregnant, lactating, or suspected pregnant patients, or male patients whose female partner is pregnant","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Undetectable HCV (Hepatitis C Virus) RNA (Ribonucleic Acid) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.7","spread":null},{"groupId":"OG001","value":"94.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Undetectable HCV RNA at 4 Weeks After Beginning of Drug Administration (RVR, Rapid Viral Response)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.6","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Undetectable HCV RNA at Completion of Drug Administration (ETR, End-of-treatment Response)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.1","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Undetectable HCV RNA at 12 Weeks After Completion of Drug Administration","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.9","spread":null},{"groupId":"OG001","value":"94.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Transition of Serum HCV RNA Levels","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.70","spread":null},{"groupId":"OG001","value":"7.05","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.80","spread":null},{"groupId":"OG001","value":"4.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.10","spread":null},{"groupId":"OG001","value":"3.30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","spread":null},{"groupId":"OG001","value":"2.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":null},{"groupId":"OG001","value":"1.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":null},{"groupId":"OG001","value":"0.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":null},{"groupId":"OG001","value":"0.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":null},{"groupId":"OG001","value":"0.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":null},{"groupId":"OG001","value":"0.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":null},{"groupId":"OG001","value":"0.50","spread":null}]}]}]},{"type":"SECONDARY","title":"Viral Sequencing at the Non-structural 3 Protease Region of HCV Virus（Result of Resistance-associated Variants Analysis)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":35},"commonTop":["Anaemia","White blood cell count decreased","Platelet count decreased","Pyrexia","Malaise"]}}}